An article from
Dive Brief
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
Published May 14, 2026
By
Biogen pushing tau drug forward despite Alzheimer’s study failure
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
605 words~3 min read
